SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Parnax Lab Ltd (506128)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506128 NSE: Pharmaceuticals & Drugs | Small Cap | Parnax Lab Share Price

₹144.05 10.15 (7.58%)

As on 02-Jul'26 16:59

Parnax Lab Ltd (506128)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506128 NSE: Pharmaceuticals & Drugs | Small Cap | Parnax Lab Share Price

₹144.05 10.15 (7.58%)

As on 02-Jul'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹165 Cr.
Current Price
₹144.1
52-Week Low / High
₹96 / 182
TTM EPS
₹0.8
TTM Sales
₹6.6 Cr.
Book Value per Share
₹20.4
P/E Ratio
186.32
Higher than its 5-year historical median
Industry PE
49.2
Price to Book (P/B)
7.06
Higher than its 5-year historical median
Price to Sales (P/S)
24.97
Higher than its 5-year historical median
EV/EBITDA
210.71
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
6.38%
Underperforms industry median
Return on Capital Employed (ROCE)
8.61%
Underperforms industry median
Return on Assets (ROA)
5.95%
Operating Profit Margin
17.6%
Net Profit Margin
19.87%
Gross Profit Margin
27.4%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-5.65%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-41.23%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
-23.63%
Asset Quality
Promoter Holding
72.30%
Pledged shares (%) of Promoter's holding (%)
9.41%
Reserves
₹12 Cr.
Equity
₹11.5 Cr.
Face Value
₹10
All Time Low / High
₹8.40 / 193.50

Parnax Lab stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Overvalued

Price Trend

Weak
Q.1 Is Parnax Lab Ltd a good quality company?
Parnax Lab Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Parnax Lab Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Parnax Lab Ltd vs industry peers?
Parnax Lab Ltd revenue CAGR is -1.78%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Parnax Lab Ltd?
Promoters hold 72.30% of the Parnax Lab Ltd, with 9.41% of their stake pledged, indicating low pledge risk.
Q.1 Stock return of Parnax Lab Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 16.5% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Parnax Lab Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -1.1%1.4%-5.4%2.9%5%-2.6%7.8%8.9%12.5%8.6%-
Value Creation
Index
-1.1-0.9-1.4-0.8-0.6-1.2-0.4-0.4-0.1-0.4-

Growth Parameters

Sales 7.25.35.86.57.72.47.27.57.477
Sales YoY Gr.--27%9.9%11.9%18.3%-69.1%201.7%4.5%-0.4%-5.7%-
Adj EPS -1.3-0.8-1.7-1-2.4-1.30.50.91.51.10.8
YoY Gr.-NANANANANANA89.8%62.4%-24.5%-
BVPS (₹) 13.712.910.29.26.95.511.116.918.419.620.4
Adj Net
Profit
-1.1-0.7-1.4-0.9-2.1-1.10.51.11.71.31
Cash Flow from Ops. 1.83.70.61.72.20.5-0.4-0.30.10.3-
Debt/CF from Ops. 9.53.319.46.7524.2-25.5-3.800-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales -0.3%-1.8%-0.6%-5.7%
Adj EPS NANA32.5%-24.5%
BVPS4.1%23.4%20.8%6.6%
Share Price 16.8% 41.4% 32.3% 41.2%

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-9.4-5.9-14.5-10.4-30.4-21.55.66.68.663.9
Op. Profit
Mgn %
-4.30.161.77-19.319.121.128.417.6-24.3
Net Profit
Mgn %
-15.8-12.6-24.6-13.2-27-47.76.814.323.318.613.4
Debt to
Equity
1.51.11.41.41.92.40.80.1000
Working Cap
Days
6265274614852573891482223144421,484
Cash Conv.
Cycle
442355178122618819493771,375

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales7566827777
Operating Expenses + 8576736656
Manufacturing Costs2111101011
Material Costs3333413333
Employee Cost 1110101111
Other Costs 1132211111
Operating Profit -00-101-01221
Operating Profit Margin (%) -5.6%0.0%-19.1%1.7%7.0%-19.3%19.1%21.0%28.4%17.6%
Other Income + 1101000011
Exceptional Items 0000000000
Interest 1111111000
Depreciation 1100000000
Profit Before Tax -1-1-2-1-0-11222
Tax -0-0-002-00010
Profit After Tax -1-1-2-1-2-11121
PAT Margin (%) -14.0%-12.6%-41.4%-12.7%-26.1%-47.7%7.6%16.1%24.5%19.9%
Adjusted EPS (₹)-1.2-0.8-2.8-1.0-2.4-1.30.61.11.61.2
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Valuation of Parnax Lab - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 1211986511192123
Share Capital 99999910111111
Reserves 320-1-3-4181011
Debt +1510121111118000
Long Term Debt13788321000
Short Term Debt2342897000
Minority Interest0000000000
Trade Payables0111111011
Others Liabilities 10-2-1-0-02101
Total Liabilities 28222018181622212225

Fixed Assets

Net Fixed Assets +7611100000
Gross Block16711111111
Accumulated Depreciation10100000111
CWIP 0000000000
Investments 11101010101010101010
Inventories0000011111
Trade Receivables7343202111
Cash Equivalents 000-1004101
Others Assets 215555571011
Total Assets 28222018181622212225

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 241220-0-000
PBT -1-1-2-1-0-11222
Adjustment 12311110-0-0
Changes in Working Capital 23-1111-2-2-2-1
Tax Paid -00000-0-0-0-0-0
Cash Flow From Investing Activity + -0000-00000-0
Capex -0-000-000-0-00
Net Investments 01-0-00-0-00-0-1
Others 0000000001
Cash Flow From Financing Activity + -2-4-1-2-2-05-3-1-0
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -20-00-6-1-1-1-00
Interest Paid 0-1-1-1-1-1-1-0-0-0
Dividend Paid 0000000000
Others -0-3-0-2616-2-10
Net Cash Flow -00-0-11-04-3-10

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-8.38-5.9-24.44-10.04-29.37-21.496.927.9596.38
ROCE (%)-1.141.42-5.432.855.04-2.577.88.8512.458.61
Asset Turnover Ratio0.240.210.270.340.430.140.370.350.350.3
PAT to CFO Conversion(x)N/AN/AN/AN/AN/AN/A-0-000
Working Capital Days
Receivable Days459.90374.90233.40184.10108.50191.9058.5071.8041.1037.40
Inventory Days4420.4021.3023.2013.5056.2035.1033.5036.2043.80
Payable Days16173.50136124.2081273.10123.2082.9069.40124.90

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *9.419.419.419.419.419.419.419.419.419.41
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Parnax Lab Ltd FAQs

The current trading price of Parnax Lab on 02-Jul-2026 16:59 is ₹144.1.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jul-2026 the market cap of Parnax Lab stood at ₹165.4 Cr

The latest P/E ratio of Parnax Lab as of 01-Jul-2026 is 186.3.

The latest P/B ratio of Parnax Lab as of 01-Jul-2026 is 7.06.

The 52-week high of Parnax Lab is ₹182.0 and the 52-week low is ₹96.25.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Parnax Lab is ₹6.62 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Parnax Lab Ltd is a below average quality company.

The key valuation ratios of Parnax Lab Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Parnax Lab Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Parnax Lab Ltd

Parnax Lab, earlier known as Krishnadeep Trade and Investments, incorporated in the year 1982, engages in investing and financial businesses in India. The company is based in Mumbai, India. In 2012 the company has changed its name from Krishna Deep Trade & Investments Ltd. to Parnax Lab Ltd.                                              "

In 2009, Krishna Deep Trade and Investments appointed Rasik Chaturvedi and Dilip Pimparkar as additional directors of the company with effect from February 16, 2009. Further, Rasik Chaturvedi and Dilip Pimparkar have also been inducted on the Audit Committee of the Company.

The registered office of the company is 136, Greet Western Building, Nagindas Master Road Extension, Fort Mumbai, Maharashtra-400001.

You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: